Skye Bioscience Inc (SKYE)

[AntonChigurh]

It is new.

Because it discusses ZYNE recent failed read outs of ZYN002. Murphy takes the high road as well, considering what Vinpat had said about the company believing ZYNE would run into trouble with transdermal patches.

“Despite the failure, Zynerba should be commended for advancing the synthetic manufacturing of cannabinoids and also coming up with a novel way of getting the drug into the body, bypassing the liver, attempting to do it transdermally,” he added. “They will probably have to go back and reengineer the product. So we’ll have to wait and see what happens. But I think Zynerba should be commended anyways.”

It will be an interesting finish to the year for sure for NMUS regarding the financing and whether they file an IND (or two) before the page turns on 2017....